We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medpace (MEDP - Free Report) ended the recent trading session at $508.52, demonstrating a +2.52% change from the preceding day's closing price. This move outpaced the S&P 500's daily gain of 0.08%. Meanwhile, the Dow experienced a drop of 0.18%, and the technology-dominated Nasdaq saw an increase of 0.1%.
Shares of the provider of outsourced clinical development services have appreciated by 3.65% over the course of the past month, outperforming the Medical sector's loss of 6.98%, and the S&P 500's loss of 1.74%.
The upcoming earnings release of Medpace will be of great interest to investors. The company's earnings report is expected on April 22, 2026. It is anticipated that the company will report an EPS of $3.74, marking a 1.91% rise compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $694.24 million, indicating a 24.29% increase compared to the same quarter of the previous year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.04 per share and revenue of $2.81 billion, indicating changes of +11.52% and +11.17%, respectively, compared to the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medpace. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Currently, Medpace is carrying a Zacks Rank of #3 (Hold).
Looking at its valuation, Medpace is holding a Forward P/E ratio of 29.1. This denotes a premium relative to the industry average Forward P/E of 15.36.
We can also see that MEDP currently has a PEG ratio of 2.38. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Medical Services industry stood at 1.38 at the close of the market yesterday.
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 146, this industry ranks in the bottom 41% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Medpace (MEDP) Laps the Stock Market: Here's Why
Medpace (MEDP - Free Report) ended the recent trading session at $508.52, demonstrating a +2.52% change from the preceding day's closing price. This move outpaced the S&P 500's daily gain of 0.08%. Meanwhile, the Dow experienced a drop of 0.18%, and the technology-dominated Nasdaq saw an increase of 0.1%.
Shares of the provider of outsourced clinical development services have appreciated by 3.65% over the course of the past month, outperforming the Medical sector's loss of 6.98%, and the S&P 500's loss of 1.74%.
The upcoming earnings release of Medpace will be of great interest to investors. The company's earnings report is expected on April 22, 2026. It is anticipated that the company will report an EPS of $3.74, marking a 1.91% rise compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $694.24 million, indicating a 24.29% increase compared to the same quarter of the previous year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.04 per share and revenue of $2.81 billion, indicating changes of +11.52% and +11.17%, respectively, compared to the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medpace. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Currently, Medpace is carrying a Zacks Rank of #3 (Hold).
Looking at its valuation, Medpace is holding a Forward P/E ratio of 29.1. This denotes a premium relative to the industry average Forward P/E of 15.36.
We can also see that MEDP currently has a PEG ratio of 2.38. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Medical Services industry stood at 1.38 at the close of the market yesterday.
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 146, this industry ranks in the bottom 41% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.